Astera Labs (NASDAQ:ALAB) Trading Down 1.9% - What's Next?
Astera Labs (NASDAQ:ALAB) shares dropped 1.9% to $284.97, despite the company exceeding Q2 2026 earnings expectations with $0.80 EPS and $392.4 million in revenue, up 104.5% year-over-year. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and a target price of $333.00, though some executives sold shares to cover tax obligations. The company is a fabless semiconductor firm focused on connectivity solutions for data centers and cloud infrastructure.
US business activity surges to 52-month high: S&P Global
U.S. business activity reached a 52-month high in August, primarily driven by a resurgence in the services sector, according to S&P Global. While manufacturing saw a slowdown due to supply delays, overall business expectations hit a nine-month high, supported by strong business investment and high equity prices. Despite this growth, consumer expectations for business conditions declined, and retail sales fell in July, suggesting a potential reduction in consumer spending in the latter half of 2026.
Grupo Supervielle (NYSE:SUPV) Shares Up 8.1% - Should You Buy?
Grupo Supervielle (NYSE:SUPV) shares rose 8.1% to $8.27 in trading, though the stock remains below its moving averages. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $13.17. The company reported quarterly EPS of $0.10 but had negative net margin and return on equity, while institutional investors like Millennium Management and Goldman Sachs increased their positions.
Agilent Technologies stock hits 52-week high at 160.36 USD
Agilent Technologies (NYSE: A) stock reached a 52-week high of $160.36, currently trading at $160.05, reflecting a 31.48% increase over the past year. Despite this milestone, InvestingPro analysis suggests the stock might be overvalued with a P/E ratio of 31.95 and is in overbought territory based on RSI. The company recently received FDA approval for a cancer diagnostic assay and EU certification for another, while Jefferies resumed coverage with a Hold rating and a $135 price target.
JPM6488826 Bond Yield and Price — FINRA:JPM6488826
This article provides detailed financial information for the JPMorgan Chase & Co. bond JPM6488826, which has a 5.65% coupon rate and matures on August 21, 2036. Key terms include an outstanding amount of 1,000.00 USD face value and annual coupon frequency. The issuer, JPMorgan Chase & Co., is described as a financial holding company with segments spanning consumer banking, investment banking, asset management, and corporate functions.
Cardano Price Prediction for August 2026—Can ADA Break $0.25 as Network Activity Surges?
Cardano's ADA token has surged over 15% to $0.2175, driven by President Trump's remarks and a bullish crypto market, with Bitcoin hitting $79,500. Network activity on Cardano has increased significantly, with daily transactions reaching 32,800 and active addresses rising to 32,800. While the Relative Strength Index (RSI) indicates overbought conditions, a decrease in open interest suggests spot-led buying, potentially making ADA vulnerable to profit-taking if it fails to break above the $0.23–$0.24 resistance zone.
Valmont Industries Stock (VMI) Opinions on Infrastructure Themes and Fund Activity
Market observers noted a major fund adding Valmont Industries (VMI) shares, linking the company to potential water infrastructure and AI-related buildouts, with price targets up to $1,097. Recent insider trading shows more sales than purchases, while Valmont reported Q2 2026 revenues of $1.1 billion, a 6.49% increase. Hedge funds displayed mixed activity, with 312 adding and 324 decreasing positions, and analysts set a median price target of $622.5.
JPMorgan Chase & Co. Has Lowered Expectations for Walmart (NASDAQ:WMT) Stock Price
JPMorgan Chase & Co. has reduced its price target for Walmart (NASDAQ:WMT) from $137.00 to $125.00, while maintaining an "overweight" rating, suggesting a potential 21% upside. This adjustment comes despite Walmart reporting better-than-expected quarterly results with EPS of $0.81 and revenue of $187.94 billion, though U.S. comparable-sales growth missed expectations and near-term guidance was soft. The broader analyst consensus for Walmart remains a "Moderate Buy" with an average target of $133.82.
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Down 4.9% - Time to Sell?
Ascentage Pharma Group International (NASDAQ:AAPG) saw its shares drop by 4.9% to $17.15 on Friday, with trading volume significantly lower than average. Despite this, analysts maintain a "Buy" rating for the stock with a consensus price target of $46.43. The company recently reported a quarterly loss of $0.65 per share on $22.24 million in revenue, while several institutional investors have either acquired new stakes or increased their existing positions.
Citigroup Inc. stock outperforms competitors on strong trading day
Shares of Citigroup Inc. (C) rallied 1.53% to $131.65, breaking a four-day losing streak, on a strong trading day where the S&P 500 Index and Dow Jones Industrial Average also saw gains. The stock's performance outpaced competitors and contributed to an overall favorable market session. This positive movement indicates a strong recovery for Citigroup.
HCA Healthcare Jumps 6.0% After JP Morgan Maintains Neutral
HCA Healthcare shares surged 6.0% to $430.79 on Friday, despite JP Morgan cutting its price target from $490 to $425 and maintaining a Neutral rating. The unexpected rally suggests investors may be looking beyond the analyst's more conservative outlook, possibly anticipating stronger operational performance or improved industry fundamentals. This divergence highlights the complexity of market sentiment around HCA, a major hospital operator, as trading volume reached 750,059 shares.
JPMorgan hiring Bank of America’s David Fishman as head of technology M&A, memo says
JPMorgan Chase is hiring David Fishman from Bank of America to lead its North America technology mergers and acquisitions within a new investment banking group focused on key tech clients. This move comes as Bank of America experiences several senior investment banker departures, though it has also made numerous managing director hires this year to bolster its teams. Fishman will join JPMorgan later this year, with Vineet Seth being elevated to vice chair of investment banking.
Packaging Corp stock holds firm after July earnings beat
Packaging Corp of America (PCA) stock is trading near its 52-week high following a strong Q2 2026 earnings beat, with EPS of $2.35 and revenue of $2.49 billion. The company also provided Q3 2026 guidance of $2.91 EPS, demonstrating steady execution and growth. Broker price targets have increased, with the average target ($264.57) suggesting upside from the current stock price ($249.87).
JPMorgan Taps BofA’s Fishman to Run Tech M&A in North America
JPMorgan Chase & Co. has appointed David Fishman, formerly of Bank of America Corp., as vice chair and head of its technology mergers and acquisitions business in North America. Fishman will also serve on a new technology M&A leadership and advisory council, focusing on key clients in the sector. The appointment aims to strengthen JPMorgan's presence in the North American tech M&A market.
Goldman, JPMorgan Are Among Most Bullish on Europe
Goldman Sachs and JPMorgan Chase strategists are highly optimistic about European stocks, driven by strong corporate earnings and an improving economic outlook. While the Stoxx Europe 600 index has already surpassed previous forecasts, risks like geopolitics and higher oil prices remain. Despite some bearish views, many analysts are confident due to resilient earnings and Europe's position in the global AI trade.
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX)
JPMorgan Chase & Co. has initiated coverage on MBX Biosciences (NASDAQ:MBX) with an "overweight" rating and an $88 price target, suggesting a 32% upside. Despite this positive outlook, MBX reported a quarterly loss of $0.78 per share, missing estimates. Other analysts show mixed sentiment, with a consensus "Moderate Buy" rating but one "sell" rating from Weiss Ratings.
Interactive Brokers Group Inc Stock (IBKR) Moved Up by 3.06% on Aug 21: What Signal Does It Send?
Interactive Brokers Group Inc (IBKR) saw its stock rise by 3.06% on August 21st, driven by dip-buying interest, strong operating metrics, and growth in customer accounts and margin debt. The company's strategic platform enhancements for international expansion also contributed to positive sentiment. Analysts have issued "Buy" ratings with an average price target of $106.31, despite risks like valuation compression and sensitivity to market volatility.
Can TROW's F/m Investments Buyout Deal Accelerate Fixed-Income Growth?
T. Rowe Price (TROW) is acquiring F/m Investments LLC, a fixed-income asset manager with $19 billion in AUM, to diversify its investment platform and expand its ETF and separately managed account (SMA) offerings. This acquisition is expected to significantly boost TROW's fixed-income and ETF AUM, leveraging its strong distribution network and capitalizing on growing client demand for specialized fixed-income strategies. The deal also aligns with TROW's broader efforts to deepen its fixed-income capabilities, as evidenced by its recent entry into the collateralized loan obligation market.
Sherwin-Williams Stock (SHW) Opinions on Recent Earnings and Insider Activity
An executive at Sherwin-Williams recently exercised options and sold shares, drawing attention to the stock's valuation and trading performance. The company also raised its full-year 2026 earnings guidance due to strong coatings demand, sparking optimism among market participants. Insider trading data shows three sales by executives in the past six months, while congressional members have both bought and sold SHW stock.
The Goldman Sachs Group Initiates Coverage on ICICI Bank (NYSE:IBN)
The Goldman Sachs Group has initiated coverage on ICICI Bank (NYSE:IBN) with a "buy" rating, contributing to an overall "Moderate Buy" consensus from analysts. This follows recent analyst actions including an upgrade from Sanford C. Bernstein and more cautious ratings from other firms. ICICI Bank shares rose to $29.89, giving the company a market capitalization of $107.24 billion, and the bank recently exceeded quarterly earnings expectations with an EPS of $0.43 and revenue of $5.97 billion.
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with an "overweight" rating and a $40 price target, suggesting a potential upside of over 25%. This positive outlook aligns with a broader analyst consensus of "Moderate Buy" and an average price target of $44.25 for the company. Despite missing earnings expectations with a loss of $0.93 per share, Stoke Therapeutics exceeded revenue forecasts, driven by its development of genetic medicines like STK-001 for Dravet syndrome.
Can TROW's F/m Investments Buyout Deal Accelerate Fixed-Income Growth?
T. Rowe Price (TROW) is set to acquire F/m Investments LLC, a fixed-income asset manager with approximately $19 billion in AUM, to diversify its investment platform and boost its ETF and SMA offerings. This acquisition is expected to increase TROW's fixed-income AUM by nearly 9% and double its fixed-income ETF AUM, capitalizing on growing demand for these investment vehicles. The deal aligns with TROW's broader strategy to expand specialized fixed-income products and strengthen its competitive position.
Invesco Cuts Fees 20% as Real Estate Fund Faces Queue
Invesco is cutting management fees by 20% for its $12.7 billion Core Real Estate—USA fund and offering a discounted tender offer to address an "elevated redemption queue" of $2.2 billion. These measures aim to ease investor withdrawals, which have represented 5.3% of the fund's net asset value since 2022. Invesco and its senior leaders will also invest up to $150 million into the fund, following a similar move by Blackstone executives earlier this year, to boost investor confidence.
Guarantor: JPMorgan Chase & Co.
JPMorgan Chase Financial Company LLC has issued $385,000 in Uncapped Digital Barrier Notes, fully and unconditionally guaranteed by JPMorgan Chase & Co. These structured investments are linked to the lesser performing of the Nasdaq-100 Futures Excess Return Index and the S&P 500 Futures Excess Return Index, maturing in August 2031. The notes offer uncapped exposure to appreciation with a contingent minimum return of 93.30%, but investors risk losing a significant portion or all of their principal if either index falls below its barrier amount.
HOWL Stock Whipsaws As One-Off Profit Meets Uncertain Future
Werewolf Therapeutics Inc. (HOWL) stock surged over 145% due to a one-time $21M payment from Jazz Pharmaceuticals, resulting in a rare $3.7M net profit and extending its cash runway into Q2 2027. Despite the positive financial news, the company faces an uncertain future as it reduced R&D spending and is exploring strategic alternatives with Piper Sandler, leading to significant stock volatility. Traders are keenly watching HOWL for potential M&A, asset sales, or clinical data readouts from its INDUKINE programs WTX-124 and WTX-330, making it a speculative, event-driven trading opportunity rather than a long-term hold.
Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price
Robert W. Baird has raised its price target for Haemonetics (NYSE:HAE) to $119 from $96, maintaining an "outperform" rating, which suggests a potential upside of 9.74%. This positive forecast aligns with a broader "Moderate Buy" consensus among analysts, with Haemonetics also reporting strong quarterly earnings that surpassed expectations. Institutional ownership in the medical instruments supplier is significant, with 99.67% of shares held by such investors.
Prudential Financial, Inc. to Participate in 2026 Barclays Global Financial Services Conference; Live Webcast Available
Prudential Financial, Inc. (NYSE: PRU) will participate in the 2026 Barclays Global Financial Services Conference on September 16, 2026. CFO Yanela Frias will lead an analyst fireside chat at approximately 9:45 a.m. ET, accessible via a live audio webcast on the company's Investor Relations website. Prudential, a global financial services leader with about $1.6 trillion in assets under management, operates across the United States, Asia, Europe, and Latin America.
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded at Zacks Research
Zacks Research has upgraded Unicycive Therapeutics (NASDAQ:UNCY) from a "strong sell" to a "hold" rating. Despite the upgrade, the stock opened at $5.45, below its moving averages, and has a "Moderate Buy" consensus rating with an average price target of $18.75. The company recently reported a quarterly loss of $0.06 per share, outperforming analyst estimates, and institutional ownership stands at 40.42%.
IMCR Looks 19.2% Undervalued on GF Value™
JPMorgan has reinitiated coverage on Immunocore Holdings PLC (IMCR) with an Overweight rating and a $50 price target, citing the strong foundation of its lead product KIMMTRAK and upcoming Phase III trial results. Despite current unprofitability, the company's Price-to-Sales ratio is significantly below its historical median, and its GF Value™ suggests it is 19.2% undervalued. The GF Score™ of 80/100 highlights strong growth and valuation, though profitability and financial strength remain areas for improvement.
Eric Trump-backed Space-Eyes to appoint ex-Delta Force officer and ex-banker, sources say
Space-Eyes, a drone technology company backed by Eric Trump, is set to appoint a former Delta Force officer, a former Morgan Stanley investment banking chief, and two other experts to its post-merger board. This move comes as the company prepares to go public through a SPAC merger with McKinley Acquisition Corp., a deal valuing the combined entity at $638 million. The new board members are intended to strengthen the company's expertise in national security, defense manufacturing, and capital markets as it scales up and expands globally.
Morgan Stanley Adjusts Price Target on DTE Energy to $148 From $153, Maintains Overweight Rating
Morgan Stanley has lowered its price target for DTE Energy (DTE) from $153 to $148, while retaining an "Overweight" rating on the stock. This adjustment reflects a revised valuation perspective for the utility company. The article also provides a brief overview of DTE Energy's business segments, including electricity production and distribution, energetic products trading, and natural gas acquisition and transmission.
25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc.
Mystic Asset Management Inc. recently acquired 25,400 shares of Supernus Pharmaceuticals (NASDAQ:SUPN) valued at approximately $1.18 million. This comes as several other institutional investors also adjusted their positions in the specialty pharmaceutical company. Despite a recent earnings miss and a stock price trading down, analysts generally maintain a "Moderate Buy" rating with an average price target of $62.83.
63,690 Shares in HNI Corporation $HNI Purchased by Oxford Financial Group LTD. LLC
Oxford Financial Group LTD. LLC recently acquired 63,690 shares of HNI Corporation, valued at approximately $2.6 million, increasing institutional ownership to 75.26%. HNI reported strong quarterly earnings, beating estimates with $1.27 EPS and a 120.7% year-over-year revenue increase. Analysts maintain a "Moderate Buy" rating with a $65 average price target, despite CEO Jeffrey D. Lorenger selling a portion of his holdings.
NFJ Investment Group LLC Takes Position in Enterprise Financial Services Corporation $EFSC
NFJ Investment Group LLC has acquired a new stake of 90,965 shares in Enterprise Financial Services Corporation, valued at approximately $5.99 million. This acquisition represents about 0.25% of the company's stock, with institutional investors collectively owning 72.21%. Analysts generally have a "Moderate Buy" rating for EFSC, with an average price target of $70, despite the company missing its recent quarterly EPS and revenue estimates, but it did increase its quarterly dividend.
NFJ Investment Group LLC Invests $2.93 Million in United Bankshares, Inc. $UBSI
NFJ Investment Group LLC has invested $2.93 million in United Bankshares, Inc. (NASDAQ:UBSI) by purchasing 63,924 shares during the second quarter. Institutional investors and hedge funds now own 70.8% of the company's stock. Analysts generally hold a "Hold" rating for UBSI, with an average target price of $47.80, following the company's recent earnings beat.
Cybin Inc. (NASDAQ:HELP) Receives Average Rating of "Buy" from Analysts
Cybin Inc. (NASDAQ:HELP) has received an average "Buy" rating from all five analysts covering the stock, with an average 12-month price target of $48.60. Recent analyst actions include TD Cowen raising its price target to $62 and Wells Fargo initiating coverage with a $16 target. Despite missing quarterly earnings estimates, institutional investors, including Millennium Management, have significantly increased their stakes in the clinical-stage psychedelic therapeutics company.
NFJ Investment Group LLC Purchases Shares of 1,483,605 Ford Motor Company $F
NFJ Investment Group LLC acquired 1,483,605 shares of Ford Motor Company, valued at approximately $20.6 million, during the second quarter. Despite this significant institutional investment, analysts maintain a cautious "Hold" rating on Ford, with a consensus price target of $15.68. The company recently reported strong quarterly earnings, surpassing expectations with $0.42 EPS and $48.3 billion in revenue, and announced a quarterly dividend of $0.15 per share.
Silvant Capital Management LLC Invests $6.90 Million in Jabil, Inc. $JBL
Silvant Capital Management LLC has acquired a new stake in Jabil, Inc. (NYSE:JBL) worth approximately $6.90 million during the second quarter. Other institutional investors, including BlackRock Inc. and Norges Bank, also significantly increased or established positions in the company. Jabil recently reported strong earnings, beating analyst estimates, and announced a quarterly dividend.
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD
Virtus Advisers LLC has made a new investment in ACADIA Pharmaceuticals Inc., purchasing over 44,000 shares valued at approximately $1.12 million. Other institutional investors like BlackRock and Norges Bank also significantly increased their stakes. Despite insider selling, analysts maintain a "Moderate Buy" consensus for ACADIA Pharmaceuticals, which recently beat earnings estimates.
Paralel Advisors LLC Acquires New Shares in EastGroup Properties, Inc. $EGP
Paralel Advisors LLC has acquired 7,395 shares of EastGroup Properties, Inc. (NYSE:EGP) valued at approximately $1.5 million in the second quarter. EastGroup Properties reported strong quarterly earnings, surpassing analyst estimates, and provided positive fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" rating for the stock, with several firms recently increasing their price targets.
Mitsubishi UFJ Asset Management Co. Ltd. Acquires Shares of 547,573 Gaming and Leisure Properties, Inc. $GLPI
Mitsubishi UFJ Asset Management Co. Ltd. has acquired 547,573 shares of Gaming and Leisure Properties, Inc. (GLPI), valued at approximately $24.4 million, making them a new institutional investor in the company. GLPI reported Q2 earnings per share in line with expectations and revenue slightly above estimates, while providing optimistic fiscal year 2026 EPS guidance. Analysts generally maintain a "Moderate Buy" rating for GLPI with an average price target of $49.91, despite some recent target reductions.
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN
NewEdge Wealth LLC has initiated a new position in Biohaven Ltd. (NYSE:BHVN), acquiring 245,670 shares valued at approximately $3.66 million during the second quarter. This investment represents about 0.16% of Biohaven's stock. Other institutional investors have also adjusted their holdings in Biohaven, while analysts have issued a range of ratings, with a consensus of "Moderate Buy" and a target price of $21.75.
Ninepoint Partners LP Buys New Stake in Canadian Imperial Bank of Commerce $CM
Ninepoint Partners LP has acquired a new stake in Canadian Imperial Bank of Commerce (NYSE:CM) during the second quarter, purchasing 58,346 shares valued at approximately $6.71 million. This makes CM the 28th largest holding for Ninepoint Partners LP, accounting for 0.5% of its portfolio. Other institutional investors have also recently adjusted their holdings in the bank, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $167.00.
Vise Technologies Inc. Takes $19.11 Million Position in Celestica, Inc. $CLS
Vise Technologies Inc. recently acquired a new position in Celestica, Inc. (NYSE:CLS), purchasing 52,378 shares valued at approximately $19.11 million. This investment comes alongside increased stakes from several other institutional investors, indicating strong institutional confidence in the technology company. Celestica has also seen recent insider selling from its CFO and CEO, while analysts have set optimistic price targets and given the stock a "Moderate Buy" consensus rating.
Virtus Advisers LLC Purchases New Shares in Veracyte, Inc. $VCYT
Virtus Advisers LLC has acquired a new position in Veracyte, Inc. (NASDAQ:VCYT), purchasing 37,574 shares valued at approximately $2.2 million. Other institutional investors like BlackRock and First Trust Advisors also increased their holdings. This comes as Veracyte reported strong quarterly earnings, beating estimates with $0.54 EPS and 15.5% year-over-year revenue growth, despite some insider selling activities.
91,094 Shares in FrontView REIT, Inc. $FVR Purchased by OVERSEA CHINESE BANKING Corp Ltd
OVERSEA CHINESE BANKING Corp Ltd has acquired 91,094 shares of FrontView REIT, Inc. (NYSE:FVR) worth approximately $1.84 million during the second quarter, representing 0.40% of the company. Other institutional investors like BlackRock also initiated significant positions. FrontView REIT recently reported earnings that beat analyst estimates but revenue fell short, and the company announced a quarterly dividend of $0.215 per share, yielding 4.3%.
Tocqueville Asset Management L.P. Takes Position in US Foods Holding Corp. $USFD
Tocqueville Asset Management L.P. has acquired a new position of 14,246 shares, valued at approximately $1.46 million, in US Foods Holding Corp. during the second quarter. This move comes as other institutional investors have also adjusted their stakes in US Foods. The article also details recent insider selling, analyst ratings, and the company's financial performance.
Wealthfront Advisers LLC Makes New Investment in Fortive Corporation $FTV
Wealthfront Advisers LLC has acquired a new position in Fortive Corporation (NYSE:FTV) during the second quarter, purchasing 92,714 shares valued at approximately $5.66 million. Other institutional investors have also modified their holdings, with institutional ownership of Fortive's stock currently standing at 94.94%. The company recently reported strong earnings, topping analyst estimates, and increased its quarterly dividend.
Trillium Asset Management LLC Makes New $6 Million Investment in MSCI Inc $MSCI
Trillium Asset Management LLC has acquired a new stake of 10,710 shares in MSCI Inc (NYSE:MSCI) worth approximately $5.998 million during the second quarter. Other institutional investors also adjusted their positions in MSCI, which maintains an average "Buy" rating and a consensus target price of $709.50 among analysts. The company recently announced a quarterly dividend of $2.05 per share, payable on August 28th.
OVERSEA CHINESE BANKING Corp Ltd Takes Position in Kimberly-Clark Corporation $KMB
OVERSEA CHINESE BANKING Corp Ltd has acquired a new stake in Kimberly-Clark Corporation, purchasing 35,470 shares valued at approximately $3.89 million. This move is part of a broader trend, as several other institutional investors and hedge funds have also recently modified their holdings in Kimberly-Clark, with institutional investors now owning 76.29% of the company's stock. The article also provides a financial overview of Kimberly-Clark, including its market capitalization, P/E ratio, recent earnings, dividend announcement, and analyst ratings, which currently average a "Hold" with a consensus price target of $117.93.
